AZD9574

Other Medications

Description

AZD9574 is an experimental medication currently being studied in clinical trials for various advanced solid cancers, including some types of breast cancer. It is being investigated to see if it is safe and effective, both when given alone (monotherapy) and in combination with other cancer drugs like temozolomide or trastuzumab deruxtecan. Some trials are specifically looking at patients whose tumors have certain genetic changes, such as mutations in BRCA1, BRCA2, or PALB2 genes. The trials are in early phases (Phase 1), meaning the main goal is to determine the best dose and understand how patients react to the drug. It is not yet approved for use in colorectal cancer or any other cancer.

Mechanism of Action

AZD9574 is being studied as a potential treatment for cancers with specific genetic mutations. The exact way it works (its specific molecular target) is still being investigated in clinical trials. It is designed to target processes involved in cancer cell growth and survival, particularly in tumors with defects in DNA repair pathways.

Side Effects

As AZD9574 is an investigational drug in early-phase clinical trials The full range of potential side effects is still being evaluated. Information from the ongoing trials will help determine the common and serious side effects associated with this medication. Participants in the trials are closely monitored for any adverse events.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT05417594 Phase 1
Recruiting
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
United States, Australia, Germany, South Korea, Spain, Sweden, United Kingdom